CD22 and diffuse large B-cell lymphoma: [43, 44] have demonstrated that co‐administration of CD19 and CD20 or CD22 could overcome antigen escape and prolong the survival of B‐ALL or DLBCL patients compared to CD19 CAR‐T therapy.